

CURRICULUM VITAE

NAME: Rubens Sievert, M.D.

MAILING ADDRESS: 300 east 40th street # 3R
New York, NY - 10016

TELEPHONE: (516) 663-3207 (office)
(917) 696-0138 (cell)
(212)682-0909 (home)

CITIZENSHIP: United States of America

SPECIALTY: **Endocrinology,Diabetes&Metabolism /**
Internal Medicine

CERTIFICATION: Board certified in Endocrinology, Diabetes & Metabolism

LICENSURE: New York State Board of Medical Licensure
1997 - #209219

EDUCATION: Combined College and Medical School
Universidad Federal de Santa Catarina
Florianopolis, SC – Brazil
Degree: Medical Doctor – summa cum laude
1982

POSTDOCTORAL TRAINING: Fellowship – Endocrinology and Metabolism
Montefiore Medical Center
111 East 210th Street, Bronx, N.Y.
7/1993 - 6/1995

Resident – Internal Medicine
The Long Island College Hospital
340 Henry Street, Brooklyn, N.Y.
6/1991 - 5/1993

Internship – Internal Medicine
The Long Island College Hospital
340 Henry Street, Brooklyn, N.Y.
6/1990 - 5/1991

Rubens Sievert, MD



Work History:

Broward Health/NBHD
Fort Lauderdale, FL 33316
01/2010 -

Winthrop University Hospital
222 Station Plaza North, Suite 350
Mineola, NY 11501
05/2000 – 10/30/2009

Elmhurst Hospital Center
79-01 Broadway
Elmhurst, NY 11373
01/1998 – 05/2000

Lincoln Medical Mental Health Center
234 E. 149 Street
Bronx, NY 10457
09/1997 – 01/1998

Montefiore Rikers Island Health Services
15-00 Hazen Street
Elmhurst, NY 11273
12/1995 – 9/1997

Hospital Ana Mery
Rua Came, 1016
Sao Paulo, SP, Brazil
01/1986-05/1990

HONORS:

Resident of the Year
The Long Island College Hospital
1993

Valedictorian, Medical School
Universidad Federal de Santa Catarina
Class of 1982

HOSPITAL APPOINTMENTS:

Director, Diabetes Program
Winthrop-University Hospital
Division, Endocrinology, Diabetes
& Metabolism
2004 - Present

Investigator, Clinical Trials Center
Winthrop University Hospital
222 Station Plaza North-Suite 300
Mineola, NY 11501
2001-Present

Director, Committee for Quality Improvement
Winthrop-University Hospital
Division, Endocrinology, Diabetes
& Metabolism
2000 - Present

Attending Physician
Elmhurst Hospital Center
79-01 Broadway
Elmhurst, N.Y. 11373
1998 – 2000

Attending Physician
Lincoln Medical and Mental Health Center
1997 – 1998

Assistant Chief Physician
Montefiore Rikers Island Health Services
15-00 Hazen Street
Elmhurst, N.Y. 11373
1995 – 1997

Attending Physician
Sao Paulo State Department of Health
Sao Paulo, SP – Brazil
1986 - 1990

Attending Physician
Hospital Anna Nery
Sao Paulo, SP - Brazil
1985 – 1990

ACADEMIC APPOINTMENTS:

Assistant Professor of Medicine
State University of New York at Stony Brook
Stony Brook, N.Y.
2001 – Present

Clinical Assistant Professor of Medicine
Mount Sinai School of Medicine
New York, N.Y.
1998 – 2000

Teaching Faculty
Montefiore Medical Center
Division, Endocrinology and Metabolism
Bronx, N.Y.
1995 - 2000

**WINTHROP-UNIVERSITY
HOSPITAL COMMITTEES:**

Co-Chair
Hospital-wide Insulin Safety Committee
2008 - Present

Member, Advisory Board
Diabetes Education Center
2001 – Present

Member, Mortality and Morbidity Committee
2000 – Present

PROFESSIONAL SOCIETIES:

The American Thyroid Association
The Endocrine Society
American Diabetes Association

PUBLICATIONS:

Aytug S, Ross FA, **Sievert R**. Occult
papillary thyroid carcinoma presenting as
extrathyroidal solitary neck cyst. Quarter
Journal of Medicine 2002;95:186-188.

Shapiro LE, **Sievert R**, Ong L, Ocampo EL
Chance RE, Lee M, Nanna M, Ferrick K,
Surks MI. Minimal cardiac effects in
athyrotic patients chronically treated with
thyrotrophin (TSH)-suppressive doses of
L-thyroxine (T4). The Journal of Clinical
Endocrinology & Metabolism 1997;82:2592-
2595..

Sievert R, Goldstein ML, Surks MI. Graves'
disease and autoimmune factor VIII
deficiency. Thyroid 1996; 6:245-247.

Surks MI, **Sievert R**. Drugs and thyroid
function. The New England Journal of
Medicine 1995; 333:1688-1694.

ABSTRACTS & PRESENTATIONS:

Valsamis A, Speiser C, Shapiro L, **Sievert R**.
Continuous insulin infusion (Cii) safely and
effectively achieves glycemic control in the
SICU after coronary artery bypass grafting.
Presented at the Endocrine Society Meeting,
Boston, MA June 2006

Mahoozi L, Jean-Pierre V, Janicka A, Norkaitis
D, Pollack S, Mikhail M, **Sievert R**, Shapiro L.
Programmed weight reduction results in
marked improvement of the metabolic
syndrome in obese diabetics. Presented at the
Endocrine Society Meeting, New Orleans, LA
June 2004

Ahmed M, Feuerman M, Shapiro L, **Sievert R**.
Impact of glycemic control on length of stay in
patients with diabetes hospitalized for
congestive heart failure. Presented at the
Endocrine Society Meeting, New Orleans, LA
June 2004.

Aytug S, Ross F, **Sievert R**.
Occult papillary thyroid carcinoma
presenting as extrathyroidal solitary
neck cyst: Report of two cases and review of
the literature. Presented at New York

Thyroid Club Fall 2000 Meeting: Focus on Thyroid Cancer, October 6, 2000

Use of New Diabetes Drugs in Chronic Kidney Disease (CKD–The Cardiac-Kidney – Diabetes Connection) **Sievert R.** Presented at the Annual Symposium on Chronic Kidney Disease New York, NY March 6, 2009.

RESEARCH EXPERIENCE:

Minimal Cardiac Effects in Athyrotic Patients Chronically Treated with Thyrotrophin (TSH) – Suppressive Doses of L-thyroxin (T4). - **1997**

A 26-Week, Multinational, Multicenter, Controlled, Open 1:1 Randomized, Parallel Clinical Trial Comparing XXX with Regular Human Insulin Injected Subcutaneously in Subjects with Type 2 Diabetes Mellitus also Using NPH Insulin.-**2001**

A 12-Week, Multinational, Multicenter, Controlled, Open 1:1:1 Randomized, Parallel Clinical Trial to Assess Non-inferiority Between Pre-and Post-Meal Administration of XXX and Pre-Meal Regular Human Insulin in Subjects w/ Type 1 Diabetes Mellitus.-**2001**

26 Week, Multinational, Multicenter, Open, Clinical Extension Trial to Assess 1 year Safety XXX Compared with Regular Human Insulin Injected Subcutaneously in Subjects with Type 2 Diabetes Mellitus Also Using NPH Insulin, Previously In ABCD.-**2001**

XXX Versus Placebo in the Treatment of Patients with Painful Diabetic Neuropathy.-**2002**

Efficacy and Safety of Inhaled Insulin Compared with Subcutaneous Human Insulin Therapy in Adult Subjects with Type 2 Diabetes Mellitus: A 2-Year, Outpatient, Open-Label, Parallel-Group Comparative Trial.-**2002**

XXX for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA).-**2003**

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel Study to Evaluate the Safety and Efficacy of the Addition of ABCD to Patients With Type 2 Diabetes with Inadequate Glycemic Control on Combined Metformin and Sulfonylurea Therapy.(025)-**2003**

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABCD Added to XXX in Patients with Inadequately Controlled Type 2 Diabetes Mellitus. (027)-**2003**

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX Added to YYY in Patients with Inadequately Controlled Type 2 Diabetes Mellitus. (028)-**2003**

A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 2 Trial to Evaluate the Safety and Efficacy of XXX as Monotherapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.-**2003**

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of XXX in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Sulfonylurea Therapy.-**2003**

A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of XXX in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who have Inadequate Glycemic Control on Metformin Therapy Alone.-**2003**

Efficacy and Safety of Inhaled Human Insulin XXX Compared with Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma: A one-Year, Multicenter, Randomized, Outpatient, Open-label, Parallel Group Comparative Trial.1028-**2004**

A One-Year, Open, Randomized, Parallel, Three-Arm Study Comparing XXX (insulin Dry Power Pulmonary Inhaler vs. YYY as Add-On Therapy Vs XXX Substitution of Sulfonylurea in Patients with Type 2 Diabetes, poorly controlled on combination Sulfonylurea and Metformin Treatment.-1017-**2004**

A Comparison of Prandial Insulin Lispro Mixtures Therapy to Glargine Basal-Bolus Therapy With Insulin Lispro on the Overall Glycemic Control of Patients With Type 2 Diabetes Previously Treated With Oral Agents Combined With Insulin Glargine.-**2004**

A Prospective, Multinational , Multicenter, Double-Blind, Randomized, Active-Controlled Trial to Compare the Effects of XXX to YYY and ZZZ Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients with High Risk Hypertension.-**2004**

Efficacy and Safety of Standard Titration Algorithm Coupled with a Conventional Dietary Intervention or Intensive Dietary Intervention Versus a Standard Titration Alone, in Patients with Type 2 Diabetes Initiating XXX Therapy-**2005**

A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere[®]/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 24-Week Follow-up-**2006**

A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects with Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere®/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow-up-**2006**

A Phase 3, 24-Week Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of Prandial Inhalation of Technosphere®/Insulin in Combination with Metformin or Technosphere®/Insulin Alone Versus 2 Oral Anti-Diabetic Agents (Metformin and a Secretagogue) in Subjects with Type 2 Diabetes Mellitus Sub-Optimally Controlled on Combination Metformin and a Secretagogue-**2006**

Glycemic Variability Predicts Endothelial Dysfunction - **2006**

A 2-Month Safety Follow-up Trial of Subjects from MannKind Protocols MKC-TI-009, MKC-TI-102, MKC-TI-103 and MKC-TI-030-**2007**

The PERSISTENT Trial: A Prospective Randomized Trial Comparing InSulin LISpro ProTamine Suspension to Insulin Glargine in Patients with Type 2 Diabetes on Anti-hyperglycemic Medications-**2007**

NIH STUDY: Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multi-vessel Disease (FREEDOM).
P.I.: Naidu S., S.I.: Marzo K., **Sievert R.**, Blair G., Awan G., Derwin T., Schubach S., Inamdar V., Wirkowski E., Goncalves J., Gala B.-**2007**

An Observational Follow-Up Study of Patients Previously Enrolled in Exubera Controlled Clinical Trials. A2171121. **2009**

DEFEND-1: Durable-Response Therapy Evaluation For Early-or New-Onset Type 1 Diabetes. Protocol TRX4 DM 006 NA 08. **2009**

A Multi-center, Randomized, Open-label, Active-controlled Study to Compare the Efficacy, Safety and Tolerability of Taspoglutide (RO5073031) Versus Insulin Glargine in Insulin-naïve Type 2 Diabetic Patients Inadequately Controlled with Metformin and Sulphonylurea Combination Therapy. Protocol: BC20965. **2009**

Observations of the Pre and Post Surgical Changes in Peptide YY (PYY) and Glucagon-like Peptide-1 (GLP-1) and its Influence on Weight Loss, Insulin Sensitivity, and Appetite. **Sievert R**, Lau R G Y. **2009**

References available upon request